Management of Idiopathic Intracranial Hypertension with Papilledema

Introduction to Treatment

The American Academy of Neurology recommends avoiding acetazolamide in patients with idiopathic intracranial hypertension (IIH) and kidney stones, due to its potential to promote kidney stone formation by reducing urinary citrate excretion and increasing urinary pH 1
The American Academy of Neurology suggests using topiramate as first-line medical therapy in patients with IIH and kidney stones, as it provides dual benefits of intracranial pressure reduction and appetite suppression leading to weight loss 1, 2

Topiramate is recommended as the first-line pharmacologic agent in patients with IIH and kidney stones, with a slow titration to therapeutic dose, despite carrying a kidney stone risk of 1.5% due to its carbonic anhydrase inhibitor properties 1, 2
The American Academy of Neurology warns patients about potential side effects of topiramate, including depression, cognitive slowing, and teratogenic effects 2
Zonisamide may be considered as an alternative to topiramate if excessive side effects occur 2

The Idiopathic Intracranial Hypertension Treatment Guidelines recommend implementing a weight loss program with a low-salt diet, targeting 5-10% weight loss, as it is the only disease-modifying treatment for IIH 3
A weight loss of 5-15% may lead to disease remission in patients with IIH 4
The American Academy of Ophthalmology recommends establishing baseline visual function with formal visual field testing, visual acuity, pupil examination, and dilated fundal examination to grade papilledema 3
Follow-up intervals for visual function monitoring depend on papilledema severity, with severe papilledema requiring monitoring every 1-3 months 4

The American Academy of Neurosurgery recommends urgent surgical intervention, such as ventriculoperitoneal (VP) shunt, if there is evidence of declining visual function or severe visual loss despite medical therapy, to preserve vision 3
A temporizing lumbar drain may be used while planning definitive surgical intervention 3